Vertex Pharmaceuticals Stock Dives After Q2 Earnings, Phase 2 Results For VX-993

Vertex Pharmaceuticals Inc (NASDAQ:VRTX) reported financial results for the second quarter after the market close on Monday. Here’s a rundown of the report.

Q2 Revenue: $2.97 billion versus estimates of $2.90 billion

Q2 Adjusted EPS: $4.52, versus estimates of $4.29

VRTX stock is slumping after-hours now. Track live prices here.

Total revenue climbed 12% year-over-year, primarily driven by the continued performance of cystic fibrosis (CF) therapies and early contributions from three ongoing launches. U.S. revenue was up 14% year-over-year and revenue outside the U.S. increased 8% year-over-year.

“Vertex delivered a strong quarter of revenue growth with each of our three product launches, ALYFTREK, JOURNAVX and CASGEVY, contributing, as well as continued advancement of our ...